Broadband ultraviolet A vs. psoralen ultraviolet A in the treatment of vitiligo: A randomized controlled trial

Clinical and Experimental Dermatology

Volumn 38, Issue 8, 2013, Pages 830-835

  El Mofty, M ^a   Bosseila, M ^a   Mashaly, H M ^a   Gawdat, H ^a   Makaly, H ^a  

^a CAIRO UNIVERSITY   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

METHOXSALEN; NEO MELADININE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; BROADBAND ULTRAVIOLET A; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; FEMALE; HUMAN; INTERMETHOD COMPARISON; MALE; OUTCOME ASSESSMENT; PHOTOTOXICITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PUVA; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL; SKIN DEFECT; SKIN PIGMENTATION; SKINFOLD; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; ULTRAVIOLET A RADIATION; VITILIGO;

ADOLESCENT; ADULT; FEMALE; HUMANS; MALE; MIDDLE AGED; PHOTOSENSITIZING AGENTS; PROSPECTIVE STUDIES; PUVA THERAPY; ULTRAVIOLET THERAPY; VITILIGO; YOUNG ADULT;

EID: 84888133644     PISSN: 03076938     EISSN: 13652230     Source Type: Journal    
DOI: 10.1111/ced.12099     Document Type: Article

References (16)

1. Kemp EH, Gavalas NG, Gawkrodger DJ, Weetman AP,. Autoantibody responses to melanocytes in the depigmenting skin disease vitiligo. Autoimmun Rev 2007; 6: 138-42.
2. McKay B, Chen F, Perumalswami CR, et al,. The tumor suppressor p53 can both stimulate and inhibit ultraviolet light-induced apoptosis. Mol Biol Cell 2000; 11: 2543-51.
3. Parsad D, Kanwar AJ, Kumar B,. Psoralen-ultraviolet A vs. narrow-band ultraviolet B phototherapy for the treatment of vitiligo. J Eur Acad Dermatol Venereol 2006; 20: 175-7.
4. Borderé AC, Lambert J, Van Geel N,. Current and emerging therapy for the management of vitiligo. Clin Cosmet Investg Dermatol 2009; 12: 15-25.
5. Bulat V, Situm M, Dediol I, et al,. The mechanisms of action of phototherapy in the treatment of the most common dermatoses. Coll Antropol 2011; 2: 147-51.
6. El-Mofty M, Mostafa W, Youssef R, et al,. Ultraviolet A in vitiligo. Photodermatol Photoimmunol Photomed 2006; 22: 214-16.
7. Wu CS, Lan CC, Wang LF, et al,. Effects of psoralen plus ultraviolet A irradiation on cultured epidermal cells in vitro and patients with vitiligo in vivo. Br J Dermatol 2007; 156: 122-9.
8. El-Mofty M, Mostafa W, Youssef R, et al,. A comparative study between different ultraviolet modalities in the treatment of vitiligo. Egypt J Dermatol Androl 2011; 31: 35.
9. Schulz KF, Altman DG, Moher D,. CONSORT statement: updated guidelines for reporting parallel group randomised trials. Br Med J 2010; 340: c332.
10. Dawson B, Trapp GT, eds. Basic and Clinical Biostatistics. Norwalk, CT: Appleton and Large, 2001.
11. Pathak MA,. Effect of UV-A, UV-B and psoralen on in vivo human melanin pigmentation. Pigment Cell 1976; 3: 291-8.
12. Mahmoud BH, Ruvolo E, Hexsel CL, et al,. Impact of long-wavelength UVA and visible light on melanocompetent skin. J Invest Dermatol 2010; 130: 2092-7.
13. Hinds GA, Heald P,. Cutaneous T-cell lymphoma in skin of color. J Am Acad Dermatol 2009; 60: 359-75.
14. Luger TA, Schwarz T,. Effects of UV light on cytokines and neuroendocrine hormones. In: Photoimmunology, (, Krutmann J, Elmets C, eds). Oxford: Blackwell Science, 1995; 55-76.
15. Kullavanijaya P, Lim H,. Photoprotection. J Am Acad Dermatol 2005; 52: 937-58.
16. Mutzhas MF, Hölzle E, Hofmann C, Plewig G,. A new apparatus with high radiation energy between 320 and 460 nm. physical description and dermatological applications. J Invest Dermatol 1981; 76: 42-7.